Hansrivijit Panupong, Trongtorsak Angkawipa, Puthenpura Max M, Boonpheng Boonphiphop, Thongprayoon Charat, Wijarnpreecha Karn, Choudhury Avishek, Kaewput Wisit, Mao Shennen A, Mao Michael A, Jadlowiec Caroline C, Cheungpasitporn Wisit
Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17104, United States.
Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, IL 60202, United States.
World J Gastroenterol. 2021 Mar 28;27(12):1240-1254. doi: 10.3748/wjg.v27.i12.1240.
Hepatitis E virus (HEV) infection is underdiagnosed due to the use of serological assays with low sensitivity. Although most patients with HEV recover completely, HEV infection among patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy can result in decompensated liver disease and death.
To demonstrate the prevalence of HEV infection in solid organ transplant (SOT) recipients.
We searched Ovid MEDLINE, EMBASE, and the Cochrane Library for eligible articles through October 2020. The inclusion criteria consisted of adult patients with history of SOT. HEV infection is confirmed by either HEV-immunoglobulin G, HEV-immunoglobulin M, or HEV RNA assay.
Of 563 citations, a total of 22 studies ( = 4557) were included in this meta-analysis. The pooled estimated prevalence of HEV infection in SOT patients was 20.2% [95% confidence interval (CI): 14.9-26.8]. The pooled estimated prevalence of HEV infection for each organ transplant was as follows: liver (27.2%; 95%CI: 20.0-35.8), kidney (12.8%; 95%CI: 9.3-17.3), heart (12.8%; 95%CI: 9.3-17.3), and lung (5.6%; 95%CI: 1.6-17.9). Comparison across organ transplants demonstrated statistical significance (Q = 16.721, = 0.002). The subgroup analyses showed that the prevalence of HEV infection among SOT recipients was significantly higher in middle-income countries compared to high-income countries. The pooled estimated prevalence of de novo HEV infection was 5.1% (95%CI: 2.6-9.6) and the pooled estimated prevalence of acute HEV infection was 4.3% (95%CI: 1.9-9.4).
HEV infection is common in SOT recipients, particularly in middle-income countries. The prevalence of HEV infection in lung transplant recipients is considerably less common than other organ transplants. More studies examining the clinical impacts of HEV infection in SOT recipients, such as graft failure, rejection, and mortality are warranted.
由于使用敏感性较低的血清学检测方法,戊型肝炎病毒(HEV)感染常被漏诊。尽管大多数戊型肝炎患者可完全康复,但在已患有慢性肝病的患者以及接受免疫抑制治疗的器官移植受者中,戊型肝炎病毒感染可能导致肝功能失代偿和死亡。
证明实体器官移植(SOT)受者中戊型肝炎病毒感染的患病率。
我们检索了截至2020年10月的Ovid MEDLINE、EMBASE和Cochrane图书馆中的符合条件的文章。纳入标准包括有实体器官移植病史的成年患者。戊型肝炎病毒感染通过戊型肝炎病毒免疫球蛋白G、戊型肝炎病毒免疫球蛋白M或戊型肝炎病毒RNA检测来确诊。
在563篇文献中,本荟萃分析共纳入了22项研究(n = 4557)。实体器官移植患者中戊型肝炎病毒感染的合并估计患病率为20.2% [95%置信区间(CI):14.9 - 26.8]。每种器官移植的戊型肝炎病毒感染合并估计患病率如下:肝脏(27.2%;95%CI:20.0 - 35.8)、肾脏(12.8%;95%CI:9.3 - 17.3)、心脏(12.8%;95%CI:9.3 - 17.3)和肺(5.6%;95%CI:1.6 - 17.9)。各器官移植之间的比较具有统计学意义(Q = 16.721,P = 0.002)。亚组分析表明,与高收入国家相比,中等收入国家实体器官移植受者中戊型肝炎病毒感染的患病率显著更高。新发性戊型肝炎病毒感染的合并估计患病率为5.1%(95%CI:2.6 - 9.6),急性戊型肝炎病毒感染的合并估计患病率为4.3%(95%CI:1.9 - 9.4)。
戊型肝炎病毒感染在实体器官移植受者中很常见,尤其是在中等收入国家。肺移植受者中戊型肝炎病毒感染的患病率明显低于其他器官移植。有必要开展更多研究来考察戊型肝炎病毒感染对实体器官移植受者的临床影响,如移植物功能衰竭、排斥反应和死亡率。